The expansion strategy centers on the company’s proprietary ingredient, Glyteine, a form of gamma-glutamylcysteine. Rajan Shah, president of Inid Research Lab, notes that the product distinguishes itself by functioning as a precursor to glutathione rather than delivering the master antioxidant in its complete form. According to Shah, this mechanism allows the supplement to bypass the body's natural regulatory hurdles, enabling cells to synthesize glutathione more effectively than traditional offerings.

Since announcing a shift toward brick-and-mortar retail in late 2025, the firm has secured placements in regional outlets and online platforms. The focus remains on leveraging clinical data to capture a market increasingly skeptical of standard glutathione formulations. By providing a building block that facilitates natural production, the company aims to maintain its momentum as it navigates the summer retail season and seeks to solidify its position in the competitive cellular health space.